First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies
Clinicaltrials.gov ID
NCT05123482
Status
Recruiting
Study Type
Interventional, Phase 1/2
Sponsor
AstraZeneca
Start Date
October 18, 2021
Anticipated End Date
June 30, 2025
Study Contact
Name: AstraZeneca Clinical Study Information Center
Phone Number:1-877-240-9479
About the Study
This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours
Conditions
Breast Cancer
Biliary Tract Carcinoma
Ovarian Cancer
Endometrial Cancer
Inclusion/Exclusion Criteria?
Primary, Secondary, Other Outcome Measures??
Locations in Canada
Foothills Medical Centre, Calgary, Alberta, T2N 4N2, Canada
BC Cancer Agency, Vancouver, British Columbia, V5Z 4E6, Canada
The Ottawa Hospital, Ottawa, Ontario, K1H 8L6, Canada
Princess Margaret Cancer Centre, Toronto, Ontario, M5G 2M9, Canada
McGill University Health Centre, Montreal, Quebec, H4A 3J1, Canada
About the Study
This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours
Conditions
Breast Cancer
Biliary Tract Carcinoma
Ovarian Cancer
Endometrial Cancer
Interventions
DRUG:
AZD8205
Locations in Canada
Foothills Medical Centre, Calgary, Alberta, T2N 4N2, Canada
BC Cancer Agency, Vancouver, British Columbia, V5Z 4E6, Canada
The Ottawa Hospital, Ottawa, Ontario, K1H 8L6, Canada
Princess Margaret Cancer Centre, Toronto, Ontario, M5G 2M9, Canada
McGill University Health Centre, Montreal, Quebec, H4A 3J1, Canada